Trial Profile

A Randomized, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iparomlimab/tuvonralimab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed; Tislelizumab
Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Qilu Pharmaceutical

30 Apr 2025 Planned number of patients changed from 650 to 608.
30 Mar 2025 Planned End Date changed from 23 Jun 2025 to 1 Dec 2029.
30 Mar 2025 Planned primary completion date changed from 23 Jun 2025 to 1 Jun 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com